JP2005505256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505256A5 JP2005505256A5 JP2003502040A JP2003502040A JP2005505256A5 JP 2005505256 A5 JP2005505256 A5 JP 2005505256A5 JP 2003502040 A JP2003502040 A JP 2003502040A JP 2003502040 A JP2003502040 A JP 2003502040A JP 2005505256 A5 JP2005505256 A5 JP 2005505256A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- antigen
- binding fragment
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 8
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 3
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 206010061481 Renal injury Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29544901P | 2001-06-01 | 2001-06-01 | |
| US29590701P | 2001-06-04 | 2001-06-04 | |
| PCT/US2002/017402 WO2002098920A1 (en) | 2001-06-01 | 2002-05-31 | Molecules and methods for inhibiting shedding of kim-1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010068988A Division JP2010150291A (ja) | 2001-06-01 | 2010-03-24 | Ｋｉｍ−１の分断を阻害するための分子および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005505256A JP2005505256A (ja) | 2005-02-24 |
| JP2005505256A5 true JP2005505256A5 (cg-RX-API-DMAC7.html) | 2006-01-05 |
| JP4527394B2 JP4527394B2 (ja) | 2010-08-18 |
Family
ID=26969139
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003502040A Expired - Fee Related JP4527394B2 (ja) | 2001-06-01 | 2002-05-31 | Ｋｉｍ−１の分断を阻害するための分子および方法 |
| JP2010068988A Withdrawn JP2010150291A (ja) | 2001-06-01 | 2010-03-24 | Ｋｉｍ−１の分断を阻害するための分子および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010068988A Withdrawn JP2010150291A (ja) | 2001-06-01 | 2010-03-24 | Ｋｉｍ−１の分断を阻害するための分子および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7041290B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1401869B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4527394B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE382060T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002305785B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2448427C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60224275T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1401869T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ530457A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002098920A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1147584C (zh) * | 1996-05-24 | 2004-04-28 | 拜奥根有限公司 | 组织再生调节物 |
| EP1305409B1 (en) * | 2000-06-16 | 2009-03-11 | Biogen Idec MA Inc. | Renal regulatory elements and methods of use thereof |
| CA2448427C (en) * | 2001-06-01 | 2013-09-24 | Biogen, Inc. | Molecules and methods for inhibiting shedding of kim-1 |
| AU2013205381B2 (en) * | 2002-03-19 | 2016-04-14 | Celldex Therapeutics, Inc. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| CA2479732A1 (en) * | 2002-03-19 | 2003-10-02 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| DK1585546T3 (da) * | 2002-12-30 | 2008-12-08 | Biogen Idec Inc | KIM- 1- Antagonister og Brug til at Modulere Immunsystem |
| AU2013242840B2 (en) * | 2003-03-19 | 2017-01-19 | Amgen Fremont Inc. | Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof |
| CA2519528C (en) * | 2003-03-19 | 2016-01-26 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
| EP1532984A1 (en) * | 2003-11-19 | 2005-05-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia |
| WO2006094134A2 (en) | 2005-03-02 | 2006-09-08 | Biogen Idec Ma Inc. | Kim-1 antibodies for treatment of th2-mediated conditions |
| CA2629453C (en) | 2005-11-10 | 2018-03-06 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
| BRPI0921237A2 (pt) | 2008-11-10 | 2015-09-22 | Alexion Pharma Inc | métodos e composições para o tratamento de distúrbios associados ao complemento |
| RU2546016C2 (ru) | 2009-12-23 | 2015-04-10 | Хилл'С Пет Ньютришн, Инк. | Композиции и способы для диагностики и лечения нарушений почек у собак |
| MX2012008108A (es) | 2010-01-11 | 2012-10-03 | Alexion Pharma Inc | Biomarcadores de efectos de inmunomodulacion en seres humanos tratados con anticuerpos anti-cd200. |
| BR112012027900A2 (pt) | 2010-04-30 | 2020-05-12 | Alexion Pharmaceuticals, Inc. | Anticorpos anti-c5a e métodos para usar os anticorpos |
| WO2012106634A1 (en) | 2011-02-03 | 2012-08-09 | Alexion Pharmaceuticals, Inc. | Use of an anti-cd200 antibody for prolonging the survival of allografts |
| WO2013078089A1 (en) * | 2011-11-22 | 2013-05-30 | Biogen Idec Ma Inc. | Anti-tim-1 antibodies and uses thereof |
| WO2015023836A1 (en) * | 2013-08-16 | 2015-02-19 | The Brigham And Women's Hospital, Inc. | Kim-1 as a therapeutic target in conditions associated with kidney fibrosis |
| US10712349B2 (en) | 2014-04-15 | 2020-07-14 | The Brigham And Women's Hospital, Inc. | Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney |
| CN110494451B (zh) | 2017-01-13 | 2023-12-01 | 塞尔达拉医疗有限责任公司 | 靶向tim-1的嵌合抗原受体 |
| EP4410317A3 (en) | 2017-04-28 | 2024-10-30 | Acuitas Therapeutics Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| IL322436A (en) | 2018-09-21 | 2025-09-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| US11453639B2 (en) | 2019-01-11 | 2022-09-27 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| FI4182297T3 (fi) | 2020-07-16 | 2025-12-05 | Acuitas Therapeutics Inc | Kationisia lipidejä käytettäväksi lipidinanohiukkasissa |
| US12129223B2 (en) | 2021-12-16 | 2024-10-29 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622861A (en) | 1994-08-05 | 1997-04-22 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA encoding hepatitis A virus receptor |
| CN1147584C (zh) * | 1996-05-24 | 2004-04-28 | 拜奥根有限公司 | 组织再生调节物 |
| EP1305409B1 (en) * | 2000-06-16 | 2009-03-11 | Biogen Idec MA Inc. | Renal regulatory elements and methods of use thereof |
| CA2448427C (en) * | 2001-06-01 | 2013-09-24 | Biogen, Inc. | Molecules and methods for inhibiting shedding of kim-1 |
| JP4572276B2 (ja) * | 2001-06-29 | 2010-11-04 | ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ | Ｔ細胞調節遺伝子およびその使用方法 |
| US7838220B2 (en) * | 2001-06-29 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes associated with immune disease |
| JP2005518782A (ja) | 2001-09-17 | 2005-06-30 | プロテイン デザイン ラブス， インコーポレイテッド | ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法 |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US7687454B2 (en) * | 2001-12-03 | 2010-03-30 | The University Of British Columbia | Effectors of innate immunity determination |
| EP4091631A1 (en) * | 2002-01-30 | 2022-11-23 | The Brigham and Women's Hospital, Inc. | A tim-3 binding molecule for use in the treatment of a disease |
| CA2479732A1 (en) | 2002-03-19 | 2003-10-02 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| CA2519528C (en) | 2003-03-19 | 2016-01-26 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
| US20050119210A1 (en) | 2003-05-20 | 2005-06-02 | Xiaobing Be | Compositions and methods for diagnosing and treating cancers |
-
2002
- 2002-05-31 CA CA2448427A patent/CA2448427C/en not_active Expired - Fee Related
- 2002-05-31 EP EP02734634A patent/EP1401869B1/en not_active Expired - Lifetime
- 2002-05-31 NZ NZ530457A patent/NZ530457A/en not_active IP Right Cessation
- 2002-05-31 DK DK02734634T patent/DK1401869T3/da active
- 2002-05-31 WO PCT/US2002/017402 patent/WO2002098920A1/en not_active Ceased
- 2002-05-31 AT AT02734634T patent/ATE382060T1/de not_active IP Right Cessation
- 2002-05-31 JP JP2003502040A patent/JP4527394B2/ja not_active Expired - Fee Related
- 2002-05-31 DE DE60224275T patent/DE60224275T2/de not_active Expired - Lifetime
- 2002-05-31 AU AU2002305785A patent/AU2002305785B2/en not_active Ceased
-
2003
- 2003-11-20 US US10/718,321 patent/US7041290B2/en not_active Expired - Lifetime
-
2006
- 2006-02-07 US US11/349,852 patent/US7300652B2/en not_active Expired - Lifetime
-
2007
- 2007-10-30 US US11/929,289 patent/US7696321B2/en not_active Expired - Lifetime
-
2010
- 2010-03-24 JP JP2010068988A patent/JP2010150291A/ja not_active Withdrawn